Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-001367
Filing Date
2025-02-14
Accepted
2025-02-14 10:10:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 18082
2 d11606712_ex99-a.htm EX-99 10201
  Complete submission text file 0000919574-25-001367.txt   30075
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Subject) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89552 | Film No.: 25624375
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201
Business Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201 214-550-1822
Avidity Partners Management LP (Filed by) CIK: 0001791827 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A